Phaseline

Targets › PTGIR

PTGIR (Prostacyclin receptor): drug programs, companies and trials

7 programs from 7 companies in 24 trials: 11 Phase 3, 6 Phase 2, 5 Phase 4, 2 Phase 1; Cardiovascular, Respiratory, Gastroenterology; next expected readout Dec 2026.

Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase. (UniProt, P43119)

Open in Phaseline: the race on PTGIR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Liquidia TechnologiesTreprostinil (LIQ861)
Prostanoid IP receptor agonist
PTGIRPhase 4Pulmonary Arterial Hypertension (PAH); Primary Pulmonary Hypertension; Pulmonary Hypertension Due to Lung Disease (Disorder); Pulmonary Arterial HypertensionMay 2027
United TherapeuticsTreprostinil
Prostanoid IP receptor agonist
PTGIRPhase 4Pulmonary Arterial Hypertension; Progressive Pulmonary FibrosisNov 2027
University of Sao Paulo General HospitalIloprost
Prostanoid IP receptor agonist
PTGIRPhase 4Pulmonary Arterial Hypertension (PAH)Jul 2028
InsmedTreprostinil
Prostanoid IP receptor agonist
PTGIRPhase 3Pulmonary Arterial Hypertension; Pulmonary Hypertension; Progressive Pulmonary Fibrosis; Hepatic Impairment …Dec 2026
Johnson & Johnson (Janssen)selexipag
Prostanoid IP receptor agonist
PTGIRPhase 3Hypertension, Pulmonary; Pulmonary Arterial HypertensionDec 2026
Pär JohanssonIloprost
Prostanoid IP receptor agonist
PTGIRPhase 2Acute Respiratory FailureSep 2027
Montreal Heart InstituteEpoprostenol Sodium
Prostacyclin receptor (IP receptor) agonist
PTGIRPhase 2Right Heart FailureMay 2028

Conditions

Pulmonary Arterial Hypertension (8) Pulmonary Arterial Hypertension (PAH) (2) Pulmonary Hypertension (2) Progressive Pulmonary Fibrosis (2) COPD (Chronic Obstructive Pulmonary Disease) (2) Hypertension, Pulmonary (2) Hepatic Impairment (1) Ischemia Reperfusion Injury (1) Acute Respiratory Failure (1) Primary Pulmonary Hypertension (1) Pulmonary Hypertension Due to Lung Disease (Disorder) (1) Right Heart Failure (1)

Modalities

small molecule (7)

Companies

University of Sao Paulo General Hospital (1) Insmed (1) Johnson & Johnson (Janssen) (1) Pär Johansson (1) Liquidia Technologies (1) Montreal Heart Institute (1) United Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.